Genmab

Genmab’s focus on antibody‑based therapies, especially epcoritamab’s early success, offers hospitals a promising yet complex option for improving DLBCL outcomes while navigating reimbursement and cost‑efficiency challenges.

Genmab’s epcoritamab shows 78‑92% response rates in elderly DLBCL patients, offering a safe, cost‑effective outpatient alternative to anthracycline or CAR‑T therapies, with strong market and reimbursement potential.

Genmab’s Q1 results show growth, but expanding the petosemtamab trial risks investor confidence; analysts stay bullish, citing pipeline strength and M&A prospects.

BNP Paribas upgrades Genmab to “outperform,” citing a strong ADC pipeline, high margins and VBR potential amid a growing oncology market.

Genmab’s 2025 AGM confirms strong antibody‑therapy growth and a $1.25 bn revenue lift, while outlining a 2026 strategy to navigate patent cliffs, value‑based pricing and potential M&A.

Genmab’s anti‑MET antibody strategy and pipeline expansion promise growth, even with a 2026 patent cliff, amid rising competition and mixed analyst outlooks.

Genmab A/S sees a moderate‑buy consensus from Jefferies, HC Wainwright, Morgan Stanley, and Truist, citing pipeline strength, royalty income and partnership growth.

Genmab’s 2026 share‑buy‑back and strong antibody‑oncology pipeline spark Jefferies “buy” notes, balancing short‑term returns with long‑term growth and a resilient revenue outlook.

Genmab’s Darzalex nets $14.4 billion in 2025, confirming its myeloma leadership, while phase‑III epcoritamab shows a 4‑month PFS gain and manageable safety, shaping future oncology strategy.

Genmab’s EPCORE DLBCL‑1 results show improved PFS but no OS win, raising questions on pricing, reimbursement and the bispecific antibody market. Read the full analysis.